| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Spero Therapeutics, Inc.$2.1
-0.03 (-1.33%)
C 50Pipeline Score Fair Value Biotech · Commercial
Market Cap
159.81 M
EPS
0.28
P/E Ratio
11.33 $
Value Trade
2.17 M
SEC Financials
Q1 2026Dilution Risk
Revenue
258.00 K
R&D Expenses
2.91 M
Operating CF
15.86 M
Total Assets
59.02 M
Total Liabilities
6.09 M
Equity
52.93 M
D/E Ratio
12,345
1.85 %
Week
-2.82 %
1 Month
15.97 %
3 Month
24.32 %
6 Month
-80.69 %
5 Year
-79.17 %
All Time
Cash Data
Cash Position
56.13 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
481.73 K
52 Week Range
0.66 - 3.22
% held by Insiders
26.06 %
% held by Institutions
14.51 %
Enterprise Value
106.15 M
Total Shares
57.92 M
Short %
4.28 %
Float Shares
42.11 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Spero Therapeutics, Inc.
482Total events
2Upcoming
126Tier-1 (high impact)
2017 – 2028Coverage
Upcoming catalysts 2
Event history 480
Jun 18, 2026
◆PDUFA DateRegulatory Filing
PDUFA date set for tebipenem HBr NDA decision
complicated urinary tract infection (cUTI), including pyelonephritissource ↗
Jun 17, 2026
▲FDA ApprovalUtebziFDA Decision
FDA approval of Utebzi for cUTIs
complicated urinary tract infections (cUTIs) including pyelonephritissource ↗
Mar 26, 2026
2026
▲Product LaunchUtebziPost-Market
Utebzi anticipated to be available to US patients by end of 2026
complicated urinary tract infections (cUTIs)source ↗
Dec 19, 2025
▲NDA SubmissionRegulatory Filing
NDA resubmission to FDA for tebipenem HBr
complicated urinary tract infections (cUTI), including pyelonephritissource ↗
Dec 2025
●NDA SubmissionRegulatory Filing
Resubmission of tebipenem HBr NDA to FDA
complicated urinary tract infections (cUTI), including pyelonephritissource ↗
Nov 13, 2025
Drug Pipeline Intelligence
C50
Pipeline Score $346M
Pipeline ValueFair Value
Valuation Signal9
Drugs Scored2.2x
rNPV / MCap Top 75%
Micro Cap (rank 229 of 911)
Percentile RankSpero Therapeutics, Inc. carries a moderate pipeline score (50/100), with $2.8B risk-adjusted pipeline value, led by TBP-PI-HBr in Urinary Tract Infection (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TBP-PI-HBr Small molecule | Urinary Tract Infection | Phase 3 | NCT06059846 | 49% | $1.0B | COMPLETED | 1,690 | - | - | Feb 6, 2025 | - | MEDIUM May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
tebipenem HBr Fast Track | complicated urinary tract infections, including pyelonephritis | Phase 3 | 2025-12-22 | The trial was stopped early for efficacy in May, 2025 following a planned interim analysis. Read More | Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis Read More | |
tebipenem HBr Fast Track | complicated urinary tract infections, including pyelonephritis | Phase 3 | 2025-12-22 | The trial was stopped early for efficacy in May, 2025 following a planned interim analysis. Read More | Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis Read More | |
tebipenem HBr Fast Track | complicated urinary tract infections, including pyelonephritis | Phase 3 | 2025-12-22 | The trial was stopped early for efficacy in May, 2025 following a planned interim analysis. Read More | Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SPRO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SPRO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SPRO▼ -6.4%on this news
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
The FDA has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs). This approval follows the successful PIVOT-PO trial, demonstrating non-inferiority to intravenous treatments. Utebzi aims to provide an effective outpatient treatment option, addressing the significant healthcare burden posed by cUTIs and antibiotic resistance.
Read more →SPROSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics reported its first quarter 2026 results, highlighting the ongoing FDA review of its New Drug Application for tebipenem HBr, aimed at treating complicated urinary tract infections. The company maintains a cash runway into 2028, despite a net loss of $7.2 million for the quarter. The Phase 3 trial for tebipenem HBr showed promising results, positioning it as a potential oral alternative to IV treatments.
Read more →SPROSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Spero Therapeutics has announced it will report its first quarter 2026 financial results and provide a business update on May 13, 2026. The report will be released after market close, and the company has stated it will not hold a conference call. This reflects Spero's commitment to keeping stakeholders informed.
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Spero Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant advancements in the tebipenem HBr program for cUTI. The company completed a global Phase 3 trial and resubmitted its NDA, with an FDA decision expected in late June. Spero is focused on fulfilling its licensing agreement with GSK while exploring new clinical-stage opportunities.
Read more →SPROSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
Spero Therapeutics announced that it will report its financial results for the fourth quarter and full year 2025 on March 26, 2026, after market close. The company focuses on developing treatments for rare diseases and areas with significant unmet medical needs. No conference call will be held to discuss these results. The announcement reflects Spero's ongoing commitment to transparency with its investors.
Read more →SPROSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero Therapeutics announced that its partner GSK has resubmitted a New Drug Application for tebipenem HBr to the FDA for treating complicated urinary tract infections. This resubmission follows positive results from the Phase 3 PIVOT-PO trial, which was halted early due to efficacy. Spero will receive a $25 million milestone payment upon submission.
Read more →SPROSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics announced the approval of 90,000 restricted stock unit awards for a new employee under its 2019 Inducement Equity Incentive Plan. This grant, approved by the Compensation Committee, is part of the company's strategy to attract talent in the clinical-stage biopharmaceutical sector. The RSUs will vest over four years, contingent on the employee's continued employment.
Read more →SPROSpero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Spero Therapeutics reported its third quarter 2025 results, highlighting the positive Phase 3 PIVOT-PO study results for tebipenem HBr, an oral antibiotic for complicated urinary tract infections. The company is collaborating with GSK to submit an FDA filing soon, with a decision anticipated in the second half of 2026. However, the SPR720 program has been discontinued following trial reviews.
Read more →SPROSpero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Spero Therapeutics will report its third quarter 2025 financial results on November 13, 2025. The company, which specializes in treatments for rare diseases and multi-drug resistant infections, will provide a business update following the report. No conference call is planned for this announcement.
Read more →SPROPIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Spero Therapeutics and GSK announced positive results from the Phase 3 PIVOT-PO trial for tebipenem HBr, an oral treatment for complicated urinary tract infections (cUTIs). The trial showed that tebipenem HBr is non-inferior to intravenous imipenem-cilastatin, with a similar safety profile. This could mark the first oral carbapenem antibiotic available for cUTIs in the U.S., addressing a significant healthcare need.
Read more →SPROSpero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
Spero Therapeutics announced that it will present data on tebipenem HBr at IDWeek 2025. This investigational oral carbapenem antibiotic is aimed at treating complicated urinary tract infections, including pyelonephritis. The Phase 3 PIVOT-PO trial has shown positive results, meeting its primary endpoint. GSK, Spero's partner, plans to file for FDA approval in late 2025.
Read more →SPRO▲ +7.3%on this news
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for e
Spero Therapeutics reported its second quarter 2025 financial results and announced that its tebipenem Phase 3 PIVOT-PO trial successfully met its primary endpoint. This achievement is a significant milestone, with the potential for tebipenem HBr to improve treatment options for complicated urinary tract infections. The company is working with GSK to complete data analysis and prepare a submission for FDA approval. Spero reported losses but continues to focus on innovation in antibiotic treatments for rare diseases and MDR infections.
Read more →SPRO▼ -6.2%on this news
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast on August 12, 2025, at 4:30 p.m. ET. During this call, the company plans to report its financial results for the second quarter of 2025 and provide an update on its business activities. The call will be accessible via phone or through the company’s Investor Relations page on its website, with an archived version available for 30 days after the event.
Read more →SPRO▲ +244.6%on this news· ran to +302% by day 3
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
Spero Therapeutics and GSK announced that the Phase 3 PIVOT-PO trial for tebipenem HBr was stopped early due to meeting its primary efficacy endpoint. The trial demonstrated non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in treating complicated urinary tract infections. The results will be included in a future NDA filing and presented at a scientific congress.
Read more →SPRO▲ +13.1%on this news
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract
Spero Therapeutics announced its first quarter 2025 operating results and provided an update on its clinical program for tebipenem HBr. The company highlighted the upcoming interim analysis of the PIVOT-PO trial, which aims to address the unmet need for treatments of complicated urinary tract infections. Despite reporting a net loss and ongoing financial challenges, Spero remains optimistic about the potential of tebipenem HBr to improve patient outcomes if approved. The company's reliance on GSK for commercialization poses additional risks to its operational strategy.
Read more →SPRO▼ -5.7%on this news
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
Spero Therapeutics will announce its first quarter 2025 financial results and provide a business update on May 13, 2025. The company, which specializes in treatments for rare diseases and multi-drug resistant infections, will release the information after market close. No conference call will follow the announcement.
Read more →SPRO▼ -5.5%on this news
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
Spero Therapeutics has appointed Esther Rajavelu as President and CEO, effective May 2, 2025. Rajavelu, who has been serving as Interim CEO since January 2025, will also be nominated to the Board of Directors. The company is prioritizing its PIVOT-PO Phase 3 trial for tebipenem HBr, while former CEO Sath Shukla will step down from his position and the Board.
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tr
Spero Therapeutics announced its fourth quarter and full year 2024 operating results, focusing on the clinical program for tebipenem HBr. This investigational oral antibiotic is aimed at treating complicated urinary tract infections and has significant potential to improve patient outcomes and reduce hospital stays. However, the company also disclosed the discontinuation of the SPR206 program and is currently evaluating data for SPR720 after pausing its development. The upcoming interim analysis of the Phase 3 PIVOT-PO clinical trial will be crucial for the future of tebipenem HBr.
Read more →SPROSpero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced it will report its financial results for the fourth quarter and full year ended December 31, 2024, on March 27, 2025. Alongside the financial results, the company plans to provide a business update during a conference call. Interested stakeholders can access the call via phone or webcast. The archived webcast will be available for 30 days on the company's website.
Read more →SPROSpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston from March 3-5, 2025. Esther Rajavelu, the Interim President and CEO, will present on March 5th and is available for one-on-one meetings. Attendees can access the presentation through Spero's website, where a replay will also be available post-event.
Read more →SPROSpero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Spero Therapeutics has announced leadership changes, with Esther Rajavelu stepping in as Interim President and CEO amid a response to a Wells Notice from the SEC. The company reported that enrollment in the Phase 3 PIVOT-PO trial of Tebipenem HBr has exceeded 60% and is on track for full enrollment by the second half of 2025. Additionally, Spero expects sufficient financial resources to fund operations into mid-2026, despite facing scrutiny over past public disclosures and ongoing clinical trials showing mixed results.
Read more →SPROCorporate Presentation January 2025 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limita
Spero Therapeutics presented forward-looking statements regarding the progress and potential approval of its oral carbapenem, Tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI). The company emphasized milestones including a Phase 3 trial enrollment completion expected in the second half of 2025 and the potential for significant market impact. However, Spero also acknowledged various risks, especially regarding FDA approval uncertainties and the need for additional funding. The company's maturing pipeline includes assets for other indications but has also faced setbacks, such as the suspension of the SPR720 program.
Read more →SPROSpero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2
Spero Therapeutics has reported its third quarter 2024 financial results and provided updates on its ongoing projects. The Phase 3 PIVOT-PO trial for tebipenem HBr is progressing well, with enrollment expected to complete in the second half of 2025. The company emphasized its extended cash runway until mid-2026, although its research and development expenses have risen significantly compared to previous quarters. Despite a reported net loss, grant revenues have increased, indicating some positive financial momentum.
Read more →SPROSpero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
Spero Therapeutics has announced it will release its financial results for the third quarter of 2024 on November 14, 2024, after market hours. The company, which specializes in developing treatments for rare diseases and multi-drug resistant infections, will not host a conference call following the announcement. This update may provide insights into Spero's ongoing projects and financial health.
Read more →SPROSpero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not m
Spero Therapeutics announced that its Phase 2a proof-of-concept study for SPR720, aimed at treating Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD), did not meet its primary endpoint after interim analysis. Although there were signs of antimicrobial activity, safety concerns led the company to suspend the development program for SPR720. Consequently, Spero will restructure its operations with a workforce reduction of about 39% to extend its cash runway into mid-2026 and focus on advancing other programs, notably tebipenem HBr and SPR206.
Read more →SPROSpero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Spero Therapeutics announced promising in vitro data on SPR719, showing a low propensity for resistance development against Mycobacterium avium complex strains. The results highlight SPR719's potential benefits as both a standalone treatment and in combination with current standard antibiotics. The data will be presented at IDWeek 2024, emphasizing the active moiety's potency and unique mechanism. This research contributes positively to the landscape of treatments for nontuberculous mycobacterium pulmonary disease, an area with significant unmet medical needs.
Read more →SPROSpero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Spero Therapeutics has published results from its Phase 1 clinical trial on SPR720, an oral prodrug for treating Nontuberculous Mycobacterial-Pulmonary Disease (NTM-PD). The data shows that SPR719, the active moiety, has significant lung uptake and favorable pharmacokinetics in pulmonary compartments. The study involved a cohort of healthy volunteers and indicated no safety issues, supporting further investigation of SPR720 as an effective treatment option. The results will be presented at the upcoming IDWeek 2024 conference.
Read more →SPROCorporate Presentation Sept 2024 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the futur
The corporate presentation discusses forward-looking statements regarding the development of SPR720 and tebipenem HBr. Notable aspects include potential patient treatment numbers, regulatory paths, and the drug's market demand. The company highlights its strategic position within a high unmet need segment, supported by a robust clinical pipeline and anticipated milestones. Risks related to FDA approval timelines and clinical development uncertainties are also addressed, illustrating the complexities of bringing these therapies to market.
Read more →SPROSpero Therapeutics to Present at Upcoming September Investor Conferences
Spero Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in upcoming investor conferences. CEO Sath Shukla will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference from September 9th to 11th, 2024, and at Cantor's Global Healthcare Conference from September 17th to 19th, 2024. These presentations aim to highlight Spero's focus on developing treatments for rare diseases and multi-drug resistant bacterial infections. Webcasts of the presentations will be available on the company's website for those unable to attend.
Read more →SPROSpero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pul
Spero Therapeutics reported its second-quarter operating results for 2024, highlighting the conclusion of patient enrollment in the Phase 2a trial of SPR720 for NTM-PD. The company remains focused on advancing its clinical programs, including the Phase 3 trial for tebipenem HBr. Despite a net loss of $17,862, Spero aims to develop innovative treatments for rare diseases and multi-drug resistant infections. Upcoming data from trials is anticipated, which could influence future development and commercialization strategies.
Read more →SPROSpero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
Spero Therapeutics, a clinical-stage biopharmaceutical company, has scheduled a conference call for August 5, 2024, to report its financial results for the second quarter of 2024. The call will also provide an update on the company's business and pipeline. Interested parties can access the call via a dedicated phone line or through a live audio webcast. The archived audio will be available on Spero's website for 30 days after the event.
Read more →SPROSpero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Sath Shukla, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. This event will take place at the NASDAQ World Headquarters in New York. Spero is focused on developing novel treatments for rare diseases and multi-drug resistant infections, with several products currently in various stages of clinical trials, including SPR720 and Tebipenem HBr. The event is expected to highlight the company’s ongoing endeavors and advancements in biopharmaceuticals.
Read more →SPROSpero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refr
Spero Therapeutics announced its financial and operational results for the first quarter of 2024, highlighting progress in its clinical pipeline. The company is on track to obtain topline data from its SPR720 Phase 2a proof-of-concept trial within the year, which could redefine treatment for non-tuberculous mycobacterial pulmonary disease. Additionally, tebipenem HBr continues in Phase 3 trials for complicated urinary tract infections, with patient enrollment expected to conclude by late 2025. Spero's strong financial position is noted, with sufficient cash reserves ensuring operational continuity until late 2025.
Read more →SPROSpero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced it will release its first quarter 2024 financial results on May 15, 2024, alongside a business update. The company is focused on developing treatments for rare diseases and multi-drug resistant infections. Key candidates include SPR720 for nontuberculous mycobacterial pulmonary disease and tebipenem HBr for complicated urinary tract infections, both of which are in advanced stages of clinical trials.
Read more →SPRO▲ +8.8%on this news
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics, a clinical-stage biopharmaceutical company, has granted restricted stock unit awards (RSUs) to a new employee as part of its 2019 Inducement Equity Incentive Plan. The grant, approved by the Compensation Committee on April 29, 2024, totals 10,833 RSUs. These units will vest over four years, beginning in May 2025, contingent on the employee's continued employment. Spero is engaged in developing treatments for rare diseases and has several investigational drugs in clinical trials.
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-exper
Spero Therapeutics reported its financial results for the fourth quarter and full year of 2023, highlighting progress in its clinical programs. The company is on track to release top-line data for SPR720, an investigational treatment for NTM-PD, in the second half of 2024. Spero is also enrolling patients in the Phase 3 PIVOT-PO trial for tebipenem HBr, a potential first-in-class oral treatment for complicated urinary tract infections. Despite reporting financial losses, Spero maintains a cash runway into late 2025.
Read more →SPROSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced that it will host a conference call on March 13, 2024, to discuss its fourth quarter and full year financial results. The call will also include updates on the company's business and pipeline. Spero is known for its focus on developing treatments for rare diseases and multi-drug resistant infections. The company is currently advancing several investigational therapies, including SPR720 and an IV-administered polymyxin product candidate, SPR206.
Read more →SPROSpero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Spero Therapeutics has received FDA clearance for its investigational new drug application for SPR206, which will be evaluated in a Phase 2 clinical study targeting MDR Gram-negative bacterial infections. This next-generation antibiotic is designed for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. The Phase 2 study will involve approximately 60 adult hospitalized patients and will assess the drug's safety, efficacy, and pharmacokinetics. The development of SPR206 addresses a significant unmet need in managing challenging bacterial infections, potentially offering clinicians a new therapeutic option.
Read more →SPROSpero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
Spero Therapeutics, a clinical-stage biopharmaceutical company, will present at Cowen's 44th Annual Healthcare Conference from March 4-6, 2024. CEO Sath Shukla is scheduled to provide insights into the company's development programs focused on rare diseases and multi-drug resistant infections. The event will include a corporate presentation and one-on-one meetings, highlighting Spero's innovative therapies, including SPR720 and tebipenem HBr. This conference represents a key opportunity for Spero to engage with investors and demonstrate the progress of its clinical pipeline.
Read more →SPROForward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential regulatory path forward for
Spero Therapeutics presented an update on its forward-looking statements regarding the potential regulatory approval of tebipenem HBr by the FDA, highlighting the future commercialization opportunities and milestones associated with this therapy. The company emphasized the expected broad access across payer channels, which could enhance market positioning. Additionally, results from ongoing clinical trials for SPR720 are anticipated in late 2024, potentially paving the way for treatment advancements in rare infectious diseases. However, the company faces risks related to additional funding requirements and reliance on third-party collaborations.
Read more →SPROSpero Therapeutics Provides Corporate Update and 2024 Outlook In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO
Spero Therapeutics provided a corporate update outlining significant milestones for 2024. The company anticipates reporting Phase 2a topline data for its lead program, SPR720, in nontuberculous mycobacterial pulmonary disease in the second half of 2024. Additionally, Spero has initiated dosing in a Phase 3 trial for tebipenem HBr in complicated urinary tract infections, supported by a $95 million milestone agreement with GSK. The company has positioned itself well with a strong cash balance expected to sustain operations into late 2025.
Read more →SPROSpero Therapeutics Announces First Patient First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections $95 million in development milestones payable over two years, as part of
Spero Therapeutics has announced the first patient visit in its Phase 3 PIVOT-PO trial for tebipenem HBr, targeting complicated urinary tract infections (cUTI). This milestone is part of a collaboration with GSK, which includes up to $95 million in development milestones. Tebipenem HBr is positioned to potentially be the first oral broad-spectrum carbapenem available in the U.S., providing an alternative to IV therapies. If successful, the trial could lead to FDA approval for tebipenem HBr in treating cUTI.
Read more →SPROSpero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with Fi
Spero Therapeutics, Inc. announced a positive financial outlook for Q3 2023, achieving total revenues of $25.5 million, a significant increase compared to $2.0 million in Q3 2022. The company provided updates on its clinical programs, highlighting the anticipated enrollment for the Phase 3 PIVOT-PO trial of tebipenem HBr in the fourth quarter of 2023. Despite a reduced net loss of $3.2 million, Spero acknowledged incurred impairment expenses related to manufacturing. The company maintains a strong cash position, anticipating funding through late 2025.
Read more →SPROSpero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, announced it will provide a business update alongside its third quarter 2023 financial results on November 13, 2023. The call will include details about their current pipeline and financial performance. The company is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, furthering their aim to address significant unmet medical needs. Their investigational drugs, including SPR720 and tebipenem HBr, are currently in development, highlighting their commitment to innovation in healthcare.
Read more →SPRO▲ +5.6%on this newsshared move
Spero Therapeutics to Present at Upcoming November Investor Conferences
Spero Therapeutics has announced that its CEO, Sath Shukla, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium on November 8-9, 2023, and will also present at the 6th Annual Evercore ISI HealthCONx Conference in Miami on November 28-30, 2023. These events provide a platform for the company to engage with investors and discuss its progress in developing treatments for multi-drug resistant infections and rare diseases. Notably, the company is focused on the investigational drug tebipenem HBr and its other product candidates.
Read more →SPRO▲ +5.6%on this newsshared move
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A
Spero Therapeutics has appointed Esther Rajavelu as Chief Financial Officer and Chief Business Officer, succeeding Stephen DiPalma. Rajavelu, who has over two decades of experience in the life sciences sector, is expected to leverage her expertise in strategic growth, financing, and M&A to help advance the company's clinical pipeline. The transition comes at a pivotal time for Spero as it prepares for important upcoming milestones in clinical and regulatory processes.
Read more →SPROSpero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference
Spero Therapeutics, a clinical-stage biopharmaceutical company, has announced that CEO Sath Shukla will be presenting at Cantor Fitzgerald’s Global Healthcare 2023 Investor Conference. This event is scheduled for September 26-28, 2023, at the Intercontinental Barclay Hotel in New York City. Spero is focused on developing treatments for multi-drug resistant infections and rare diseases, with product candidates such as SPR720 and tebipenem HBr in the pipeline.
Read more →SPROSpero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Spero Therapeutics will present its developments at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. The company is focused on creating targeted treatments for rare diseases and multi-drug resistant bacterial infections. Key presentations will include updates on investigational drugs such as tebipenem HBr, which has not yet received FDA approval, and SPR720. The event provides a platform for Spero's CEO, Sath Shukla, to engage in one-on-one discussions with investors.
Read more →SPROSpero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First
Spero Therapeutics reported its second quarter 2023 operating results, highlighting a Special Protocol Assessment agreement with the FDA for the Phase 3 PIVOT-PO trial of Tebipenem HBr, which is anticipated to begin in Q4 2023. The company also noted a significant reduction in net loss compared to the same period in the previous year, with a loss of $11.9 million. Revenue rose slightly to $2.7 million, attributed to revenue recognition from a transaction with GSK. Spero plans further clinical developments, including trials for SPR720 and SPR206, alongside a conference call to discuss these updates.
Read more →SPROSpero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, will host a conference call on August 10, 2023, to discuss its second quarter 2023 financial results and business updates. The company is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Key products under development include SPR720 for a rare lung disease and tebipenem HBr for complicated urinary tract infections. This update highlights Spero's ongoing commitment to addressing significant medical needs.
Read more →SPRO▲ +14.8%on this newsshared move
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to rece
Spero Therapeutics has announced a Special Protocol Assessment Agreement with the FDA for its pivotal Phase 3 PIVOT-PO trial of tebipenem HBr, aimed at treating complicated urinary tract infections. This agreement supports the trial's protocol design and could lead to the first oral carbapenem antibiotic for such infections, addressing a growing need due to antibiotic resistance. The trial is expected to begin in Q4 2023, and Spero stands to gain $30 million and additional milestone payments from GSK as it progresses through its development.
Read more →SPRO▼ -5.8%on this news
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, t
Spero Therapeutics has announced the appointment of Sath Shukla as its new President and Chief Executive Officer, effective August 1, 2023. Shukla, who previously served as the Chief Financial Officer, brings over 20 years of experience in strategic and financial leadership. He will succeed Ankit Mahadevia, who transitions to the role of Chairman of the Board. This leadership change is seen as a pivotal moment in Spero's growth strategy focused on addressing serious infections and rare diseases.
Read more →SPROSpero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H
Spero Therapeutics reported its first quarter 2023 results, indicating a continued focus on its clinical development programs. The company's Phase 2 trial for SPR720 in nontuberculous mycobacterial pulmonary disease is progressing toward a top line data readout expected in the first half of 2024. Additionally, Spero is engaged with the FDA for a Special Protocol Assessment related to a pivotal Phase 3 trial for tebipenem HBr, anticipated to begin later this year. Notably, the company's net loss has decreased compared to the previous year, reflecting improvements in cost management.
Read more →SPROSpero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Spero Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 11, 2023, to discuss its first quarter financial results and provide a business update. The company is focused on developing treatments for high unmet needs, particularly in rare diseases and multi-drug resistant infections. Key products in development include SPR720 for a rare pulmonary disease and tebipenem HBr for complicated urinary tract infections.
Read more →SPROSpero Therapeutics to Present at Upcoming Investor Conference
Spero Therapeutics announced that its management team will present at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. The company is engaged in the development of innovative therapies for bacterial infections and rare diseases. Key products under development include SPR720, targeting non-tuberculous mycobacterial infections, and tebipenem HBr, which is still awaiting FDA approval. The presentation aims to provide insights into Spero's ongoing clinical trials and future plans.
Read more →SPROSpero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
Spero Therapeutics announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases, scheduled for April 15-18, 2023, in Copenhagen. The presentations focus on the in vitro activity of its candidate SPR206 against multi-drug resistant bacterial infections, alongside comparator compounds. This event underscores Spero's ongoing commitment to addressing high unmet medical needs in the field of infectious diseases.
Read more →SPROExhbit 99.1 Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disea
Spero Therapeutics has reported its financial results for the fourth quarter and full year 2022, highlighting a significant revenue increase driven by collaborations with GSK and Pfizer. The company has initiated a proof-of-concept Phase 2 trial for its drug SPR720 targeting nontuberculous mycobacterial pulmonary disease, with top-line data expected in the first half of 2024. Spero also secured a $66 million upfront payment from an exclusive licensing deal with GSK, enhancing its financial position. However, the company posted a substantial overall net loss for the year amid restructuring efforts.
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update
Spero Therapeutics reported its Q4 and full-year 2022 financial results, announcing the initiation of a Phase 2 trial for SPR720 targeting nontuberculous mycobacterial pulmonary disease, with top-line results expected in the first half of 2024. The company finalized a licensing agreement with GSK for tebipenem HBr, receiving an upfront payment of $66 million and further investment. Looking ahead, Spero plans to advance multiple clinical trials and has engaged with the FDA regarding its drug development programs.
Read more →SPROSpero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
Spero Therapeutics has postponed its fourth quarter and full year 2022 earnings release and conference call from March 13 to March 30, 2023. The delay is attributed to the company's ongoing evaluation of the accounting treatment related to the GSK transaction in 2022, requiring extra time for audit completion. The planned conference call will discuss financial results and updates on the business and pipeline following the earnings release.
Read more →SPROSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
Spero Therapeutics has announced a conference call scheduled for March 13, 2023, to discuss its fourth quarter and full year 2022 financial results. The call will also provide updates on the company's business and development pipeline, which includes therapies for rare diseases and multi-drug resistant infections. Spero is particularly focused on its investigational drugs, including SPR720 and SPR206. The company aims to address significant unmet medical needs in the biopharmaceutical field.
Read more →SPROSpero Therapeutics to Present at Upcoming Investor Conferences
Spero Therapeutics announced that its CEO, Ankit Mahadevia, will present at the Cowen 43rd Annual Healthcare Conference and the Oppenheimer 33rd Annual Healthcare Conference. The events will provide an opportunity for investors to engage in one-on-one meetings. Spero's focus on developing treatments for rare and multi-drug resistant bacterial infections underscores its commitment to addressing unmet medical needs in this area. Details regarding the presentations and their respective webcasts have been provided.
Read more →SPROSpero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and mult
Read more →SPROSpero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spe
Read more →SPROSpero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investm
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for p
Read more →SPROSpero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug r
Read more →SPRO▼ -11.3%on this news
Spero Therapeutics to Present Data at IDWeek 2022
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug r
Read more →SPROSpero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School) CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.
Read more →SPRO▲ +167.7%on this news
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 mill
Read more →SPROSpero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). “Kamal joins Spero with an impressive track record of building and leading successful anti-i
Read more →SPRO▲ +55.5%on this news· ran to +97% by day 1shared move
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration Alignment with the FDA on a regulatory path forward for the continued development of tebipenem
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single
Read more →SPRO▲ +9.5%on this news
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expect
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Re
Read more →SPRO▼ -5.4%on this newsshared move
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an
Read more →SPROSpero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors with Losses of $100,000 can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class
Read more →SPROSpero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application CAMBRIDGE, Mass., June 27, 2022 Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from
Read more →SPROSPERO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc.
LEAD PLAINTIFF DEADLINE IS JULY 25, 2022 NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the Company“) (NASDAQ: SPRO) in the
Read more →SPROSpero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem s Optimal Path to Value Cr
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuber
Read more →SPRO▼ -8.7%on this newsshared move
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update
Read more →SPRO▼ -63.7%on this news
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advance
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206 Spero to Explore Strategic Partn
Read more →SPRO▼ -7.3%on this news
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022,
Read more →SPROSpero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine CAMBRIDGE, Mass., April 6, 2022 Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update Provides update on ongoing FDA review of Tebipenem HBr NDA Phase 2 trial of SPR720 in nontuberculous mycobacte
Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update Provides update on ongoing FDA review of Tebipenem HBr NDA Phase 2 trial of SPR720 in nontuberculous mycobacterial-pulmonary disease on track for initiation in 2H 202
Read more →SPROSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results
Read more →SPROSpero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting shown to be we
Read more →SPROForward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential approval by the U.S. Food a
Corporate Presentation January Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential approval by the U.S. Food and Drug Administration (FDA
Read more →SPROSpero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients New award option exercised by BARDA brings the total potenti
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up CAMBRIDGE, Mass., January
Read more →SPROSpero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being develope
Read more →SPROSpero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis The FDA has set a Prescription
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27,
Read more →SPROSpero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update Submitted NDA to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections, including pyelonephrit
Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update Submitted NDA to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections, including pyelonephritis Entered into a non-dilutive revenue interest financin
Read more →SPROSpero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPRO▲ +7.3%on this news
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis CAMBRIDGE, Mass., October 28, 2021 Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmace
Read more →SPROSpero Therapeutics Appoints Kathleen Tregoning to its Board of Directors Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero s Board
Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero s Board CAMBRIDGE, Mass., October 12, 2021 Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinic
Read more →SPROSpero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners for Up to $125 Million
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacteria
Read more →SPROSpero Therapeutics to Present Data at IDWeek 2021
CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacteria
Read more →SPROSpero Therapeutics to Present at Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update Tebipenem HBr on track for NDA submission in the fourth quarter of 2021 Announced $40 million equity investment from Pfizer
Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update Tebipenem HBr on track for NDA submission in the fourth quarter of 2021 Announced $40 million equity investment from Pfizer Inc. and licensing agreement for SPR206 Initiated Phase 1
Read more →SPROSpero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206 Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territori
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206 Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial mil
Read more →SPROSpero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics to Participate at the Berenberg Conference USA
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial i
Read more →SPROSpero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update Tebipenem HBr remains on track for NDA submission in the second half of 2021 Conference call and live webcast at 4:30 p.m. ET
Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update Tebipenem HBr remains on track for NDA submission in the second half of 2021 Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., May 6, 2021 Spero Therapeutics,
Read more →SPROSpero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update Tebipenem HBr advancing towards NDA submission in the second half of 2021 Conference call and live webcast at
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update Tebipenem HBr advancing towards NDA submission in the second half of 2021 Conference call and live webcast at 4:30 p.m. EST today CAMBRIDGE, Mass., March 11, 2021 Sper
Read more →SPROSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics to Present at Investor Conferences in March
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial CAMBRIDGE, Mass., February 5, 2021 Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unme
Read more →SPROSpero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerciali
Read more →SPROSpero Therapeutics Added to the NASDAQ Biotechnology Index
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bact
Read more →SPROForward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design, initiation, timing and submis
Corporate Presentation Evercore ISI HealthCONx Conference December 3, 2020 Exhibit 99.1 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design
Read more →SPROSpero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance Conference call and live webca
Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance Conference call and live webcast at 4:30 p.m. EST today CAMBRIDGE, Mass., November 5, 2
Read more →SPROSpero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020
CAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections
CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics to Present at Investor Conferences in September
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces Pricing of Securities Offering
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bact
Read more →SPROSpero Therapeutics Announces Proposed Public Offering
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bact
Read more →SPROForward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the initiation, timing and submission to
Corporate Presentation September 16, 2020 Cantor Healthcare Conference Exhibit 99.1 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the initiation
Read more →SPROSpero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis Well-tolerated with comparable safety profile to intrav
Read more →SPROSpero Therapeutics Announces FDA Acceptance of IND Application for SPR720
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacte
Read more →SPROSpero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update Top-line data for Phase 3 ADAPT-PO trial evaluating oral tebipenem HBr in complicated urinary tract infection expected in 3Q
Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update Top-line data for Phase 3 ADAPT-PO trial evaluating oral tebipenem HBr in complicated urinary tract infection expected in 3Q20 Conference call and live webcast at 4:30 p.m. EDT toda
Read more →SPROSpero Therapeutics to Provide Business Update and Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROForward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the initiation, timing, progress and resu
Corporate Presentation June 4, 2020 Jefferies Healthcare Conference Exhibit 99.1 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the initiation, t
Read more →SPROSpero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSPERO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm
NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spero Therapeutics, Inc. ("Spero" or the "Company")(NASDAQ:SPRO). If you invested in Spero stock and would like to discuss your lega
Read more →SPROSpero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update Tebipenem HBr Phase 3 trial enrollment complete with top-line data expected in the third quarter of 2020 SPR720 Phase 2a NTM
Spero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update Tebipenem HBr Phase 3 trial enrollment complete with top-line data expected in the third quarter of 2020 SPR720 Phase 2a NTM trial initiation planned for the second half of 2020 Conf
Read more →SPROSpero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial i
Read more →SPROSpero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial i
Read more →SPROSpero Announces Appointment of Scott Jackson to its Board of Directors Spero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veter
Spero Announces Appointment of Scott Jackson to its Board of Directors Spero brings significant commercial leadership and business development experience to its Board of Directors with appointment of pharmaceutical veteran, Scott CAMBRIDGE, Mass., April 16, 2020 -- Spero Therap
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update 2020 catalysts include tebipenem HBr pivotal Phase 3 top-line cUTI data in 3Q20 and SPR720 Phase 2a NTM trial
Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update 2020 catalysts include tebipenem HBr pivotal Phase 3 top-line cUTI data in 3Q20 and SPR720 Phase 2a NTM trial CAMBRIDGE, Mass., March 16, 2020 Spero Therapeutics, Inc.
Read more →SPROSpero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection
CAMBRIDGE, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics Announces Closing of Rights Offering
CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROSpero Therapeutics to Present at March Investor Conferences
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial i
Read more →SPROSpero Therapeutics Announces Commencement of Rights Offering
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial
Read more →SPROFORM OF INSTRUCTIONS AS TO USE OF SPERO THERAPEUTICS, INC. SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE INFORMATION AGENT, YOUR BANK OR YOUR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offeri
FORM OF INSTRUCTIONS AS TO USE OF SPERO THERAPEUTICS, INC. SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE INFORMATION AGENT, YOUR BANK OR YOUR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offering (the Rights Offering ) by Spero Therapeutics, Inc., a
Read more →SPROSpero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bact
Read more →SPROSpero Therapeutics Announces Proposed Rights Offering $30 Million fully backstopped rights offering will be available to all stockholders of record on
Spero Therapeutics Announces Proposed Rights Offering $30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020 CAMBRIDGE, Mass., January 30, 2020 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset c
Read more →SPROSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bact
Read more →SPROSECOND AMENDMENT TO LEASE AGREEMENT This SECOND AMENDMENT TO LEASE (the Second Amendment ) dated this 16th day of December, 2019 (the Effective Date ) is made by and between U.S. REIF CENTRAL PLAZA MASSACHUSETTS, LLC , a
SECOND AMENDMENT TO LEASE AGREEMENT SECOND AMENDMENT TO LEASE (the Second Amendment ) dated this 16th day of December, 2019 (the Effective Date ) is made by and between U.S. REIF CENTRAL PLAZA MASSACHUSETTS, LLC, a Delaware limited liability company (the Landlord ), and SPERO T
Read more →SPROSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bact
Read more →SPROSpero Therapeutics to Host Key Opinion Leader Symposium in December
CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bact
Read more →SPROSpero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review SPR994 pivotal Phase 3 cUTI trial actively enrolling with data expected in the third quarter of 2020
Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review SPR994 pivotal Phase 3 cUTI trial actively enrolling with data expected in the third quarter of 2020 CAMBRIDGE, Mass., November 4, 2019 Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi
Read more →SPROSpero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial
Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial CAMBRIDGE, Mass., October 3, 2019 - Spero Therapeutics, Inc. (Nasd
Read more →SPROSpero Therapeutics Announces Presentations at IDWeek 2019
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bact
Read more →SPROSpero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update SPR994 pivotal Phase 3 cUTI trial enrollment continues; multiple clinical pipeline catalysts expected in 2H19
Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update SPR994 pivotal Phase 3 cUTI trial enrollment continues; multiple clinical pipeline catalysts expected in 2H19 CAMBRIDGE, Mass., August 8, 2019 Spero Therapeutics, Inc. (Nasdaq:SPRO),
Read more →SPROSpero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206
CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacte
Read more →SPROSpero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis
CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacte
Read more →SPROSpero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacte
Read more →SPROSpero Announces $10 Million Registered Direct Offering of Common Stock Novo Holdings A/S through its Novo REPAIR Impact Fund to Invest Up to $10 million Net Proceeds to Advance Spero s SPR720
Spero Announces $10 Million Registered Direct Offering of Common Stock Novo Holdings A/S through its Novo REPAIR Impact Fund to Invest Up to $10 million Net Proceeds to Advance Spero s SPR720 CAMBRIDGE, Mass., June 13, 2019 Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset
Read more →SPROSpero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review SPR994 pivotal Phase 3 trial underway and screening patients; multiple clinical catalysts ahead in 2H19
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review SPR994 pivotal Phase 3 trial underway and screening patients; multiple clinical catalysts ahead in 2H19 CAMBRIDGE, Mass., May 9, 2019 Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-a
Read more →SPROSpero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced toda
Read more →SPROSpero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bact
Read more →SPROSpero Announces Appointment of Cynthia Smith to its Board of Directors Spero adds significant commercial leadership and product launch expertise to its Board of Directors with appointment of Cynthia Smith
Spero Announces Appointment of Cynthia Smith to its Board of Directors Spero adds significant commercial leadership and product launch expertise to its Board of Directors with appointment of Cynthia Smith Mass., March 19, 2019 Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-as
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line D
Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19
Read more →SPROSpero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today
Read more →SPROSpero Therapeutics Announces FDA Acceptance of IND Application for SPR994
CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacte
Read more →SPROSpero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial
CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, announced
Read more →SPROSpero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial CAMBRIDGE, Mass., January 7, 2018 Spero Therapeutics, Inc. (Nasdaq:SPRO), a mu
Read more →SPROSpero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI
FDA meeting supports single pivotal Phase 3 clinical trial of SPR994 in cUTI SPR994 IND submitted and ADAPT-PO Phase 3 startup activities underway CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmac
Read more →SPROForward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, development plans, regulatory activities,
Company Presentation November 13, 2018 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, development plans, regulatory activities, anticipated milest
Read more →SPROSpero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation aroun
Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., November 8, 2018 Spero T
Read more →SPROSpero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today a
Read more →SPROSpero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206
CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today
Read more →SPROSpero Announces Positive SPR994 Phase 1 SAD/MAD Final Results Multiple ascending dose clinical data supports advancement of 600 mg TID dose for pivotal Phase 3 clinical trial, planned for initiation around year-end 2018
Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results CAMBRIDGE, Mass., September 27, 2018 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotics
Read more →SPROSpero Therapeutics Announces Presentations at IDWeek 2018
CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, announce
Read more →SPROSpero Therapeutics to Present at the Cantor Global Healthcare Conference in October
CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced toda
Read more →SPROSpero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference
Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity and favorable toxicology, and urinary tract infection epidemiology CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (N
Read more →SPROSpero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors Spero adds broad leadership and scientific expertise to its Board of Directors with appointment of John Pottage
Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors Spero adds broad leadership and scientific expertise to its Board of Directors with appointment of John Pottage CAMBRIDGE, Mass. August 14, 2018 Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-ass
Read more →SPROSpero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-tra
Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview CAMBRIDGE, Mass., August 9, 2018 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and comme
Read more →SPROSpero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994 Planned pi
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development CAMBRIDGE, Mass., July 16, 2018 Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotics to
Read more →SPROSpero Therapeutics Announces Proposed Offering of Common Stock
Spero Therapeutics Announces Proposed Offering of Common Stock CAMBRIDGE, Mass., July 9, 2018 Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for mult
Read more →SPROSpero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994 Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses Data support selection of SPR994 300 mg TID dose for use in
Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994 CAMBRIDGE, Mass., July 9, 2018 Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotics to treat multi-
Read more →SPROSpero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018
Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum of activity and equivalence to IV carbapenems CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical
Read more →SPROSpero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today
Read more →SPROSpero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and tolerability of SPR741 when co-administered with b-lactam antibiotics and continues to build
Read more →SPROSpero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update Multiple data readouts expected throughout 2018 and SPR994 Phase 3 initiation anticipated around year-end 2018
Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update Multiple data readouts expected throughout 2018 and SPR994 Phase 3 initiation anticipated around year-end 2018 CAMBRIDGE, Mass., May 10, 2018 Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-a
Read more →SPROSpero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today
Read more →SPROSpero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced toda
Read more →SPROSpero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announce
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update Poised to transition SPR994 from Phase 1 to Phase 3 around year-end 2018
Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update Poised to transition SPR994 from Phase 1 to Phase 3 around year-end 2018 CAMBRIDGE, Mass., April 2, 2018 Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical
Read more →SPROSpero Announces Appointment of David P. Southwell to its Board of Directors Broad leadership and financial expertise adds to our board s breadth of talent and background
Spero Announces Appointment of David P. Southwell to its Board of Directors Broad leadership and financial expertise adds to our board s breadth of talent and background CAMBRIDGE, Massachusetts, February 1, 2018 Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-st
Read more →SPROFIRST AMENDMENT TO LEASE AGREEMENT This FIRST AMENDMENT TO LEASE (the Amendment ) dated this 17th day of January, 2018 (the Effective Date ) is made by and between U.S. REIF CENTRAL PLAZA MASSACHUSETTS, LLC , a Delaware
FIRST AMENDMENT TO LEASE AGREEMENT FIRST AMENDMENT TO LEASE (the Amendment ) dated this 17th day of January, 2018 (the Effective Date ) is made by and between U.S. REIF CENTRAL PLAZA MASSACHUSETTS, LLC, a Delaware limited liability company (the Landlord ), and SPERO THERAPEUTIC
Read more →SPROSpero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced
Read more →SPROSpero Therapeutics Announces 3Q17 Operating Results and Pipeline Update Raised approximately $83.6 million in gross proceeds from Initial Public Offering Advanced pipeline with initiation of SPR994 Phase 1 trial in Octob
Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update CAMBRIDGE, Mass., December 14, 2017 Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments fo
Read more →SPROSpero Therapeutics, Inc. (Nasdaq: SPRO) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, will visit the Nasda
Read more →SPROSpero Therapeutics Announces Underwriters’ Option Exercise
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announc
Read more →SPROSpero Therapeutics Announces Closing of Initial Public Offering
Spero Therapeutics Announces Closing of Initial Public Offering CAMBRIDGE, Mass., November 6, 2017 Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant
Read more →SPROSpero Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the pricing
Read more →SPROSpero Therapeutics Launches Initial Public Offering
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced that it has
Read more →SPROSpero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
Clinical study to evaluate potential first ever orally administered carbapenem being developed for multi-drug resistant (MDR) Gram-negative infections Initiation of pivotal Phase 3 clinical trial in patients with complicated urinary tract infections (cUTI) planned for second hal
Read more →SPROSpero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults
-Spero and Meiji Seika Pharma Co., LTD. announce an exclusive license partnership for SPR994 -FDA grants SPR994 Qualified Infectious Disease Product (QIDP) status for complicated urinary tract infections (cUTI), diabetic foot infections (DFI) and community acquired bacterial pne
Read more →SPROSpero Therapeutics Files Registration Statement for Proposed Initial Public Offering
CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (“Spero”), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced th
Read more →SPROSpero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced data from th
Read more →SPROSpero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team
Cristina Larkin promoted to Chief Operating Officer Timothy Keutzer Promoted to Senior Vice President, Development CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a biopharmaceutical company founded to develop novel therapies for the treatment of
Read more →Competitive Position
How SPRO ranks across every disease it competes inCompetitive Position is a premium feature
See how SPRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial